Delhi HC restrains 4 pharma firms from making, selling 2 Novartis patent drugs

In a major relief to Novartis, the Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major Novartis AG.

The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech, generic pharma firms making or selling Valsartan and Sacubitril.

For more details, check out the full story on the link below:

HC Restrains 4 Pharma Firms From Making, Selling Novartis Sacubitril, Valsartan Tablets